Most active New York Stock Exchange-traded stocks
AP - Thu Oct 16, 5:03PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
GE: 24.25 (-0.03), F: 13.98 (+0.36), RF: 9.06 (-0.04), AMD: 2.64 (+0.03), PFE: 27.70 (-0.49), BAC: 16.08 (+0.32), TWTR: 48.23 (-1.76), RAD: 4.61 (-0.06)
Final Glance: Pharmaceuticals companies
AP - Thu Oct 16, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 96.78 (-1.43), BAX: 68.18 (-0.16), PFE: 27.70 (-0.49), BMY: 49.22 (+0.26)
FDA panel votes to keep boxed warning on Chantix
AP - Thu Oct 16, 3:10PM CDT
WASHINGTON (AP) — Federal health advisers say a bold-letter warning about suicide risks with Pfizer's Chantix should remain on the anti-smoking drug until it can reevaluated based on new, rigorous study information.
PFE: 27.70 (-0.49)
Baxter Q3 Beats As Hemophilia Drugs Fend Off Rivals
at Investor's Business Daily - Thu Oct 16, 2:07PM CDT
Medical products giant Baxter International (BAX) beat Q3 earnings estimates and lifted its 2014 organic sales growth guidance Thursday, though it lowered its EPS outlook due to a divestiture. Its stock initially dropped but by early afternoon was up...
BIIB: 302.74 (-2.95), BAX: 68.18 (-0.16), PFE: 27.70 (-0.49)
Can health-care stock funds stay on top?
By STAN CHOE - AP - Thu Oct 16, 1:54PM CDT
NEW YORK (AP) — When swings in the stock market cause anxiety to spike, like it is now, many investors aim to get healthy.
JNJ: 96.78 (-1.43), MRK: 53.43 (-1.30), PFE: 27.70 (-0.49)
Midday Glance: Pharmaceuticals companies
AP - Thu Oct 16, 12:21PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 96.78 (-1.43), BAX: 68.18 (-0.16), PFE: 27.70 (-0.49), BMY: 49.22 (+0.26)
Early Glance: Pharmaceuticals companies
AP - Thu Oct 16, 10:35AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 96.78 (-1.43), BAX: 68.18 (-0.16), PFE: 27.70 (-0.49), BMY: 49.22 (+0.26)
Shire Can Thrive Without AbbVie, Say Analysts
at Investor's Business Daily - Thu Oct 16, 10:19AM CDT
Specialty drugmaker Shire faced a future as a stand-alone company Thursday after AbbVie directors late Wednesday voted against a planned acquisition. Investors and analysts seemed optimistic, though, as Shire (SHPG) stock was up 3% in early trading...
AGN: 178.00 (+0.41), PFE: 27.70 (-0.49), SHPG: 178.46 (+7.97), ABBV: 52.90 (-1.73)
3 Small-Cap Biotech Stocks to Buy if the Market Crashes
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 15, 1:38PM CDT
The Russell 2000 small-cap stock index is the most widely used proxy for small-cap stocks and the exchange traded fund that tracks that index has tumbled 11.6% this year. That's a frightening drop, but it's been proven time and time again that...
JNJ: 96.78 (-1.43), INSY: 38.38 (+1.10), PTLA: 25.90 (+0.08), PFE: 27.70 (-0.49), MRK: 53.43 (-1.30), OPHT: 40.51 (-0.24), IWM: 107.80 (+1.20), BMY: 49.22 (+0.26), REGN: 340.71 (+5.96)
Shire Falls, AbbVie Questioned On Buyout Backtrack
at Investor's Business Daily - Wed Oct 15, 12:11PM CDT
Shares of specialty drugmaker Shire plummeted 23% on the stock market today after word got out late Tuesday that big pharma AbbVie is reconsidering its $55 billion buyout of the company. Shire (SHPG) confirmed the reports Wednesday morning with a...
ABT: 39.99 (-0.02), AZN: 67.56 (-0.85), PFE: 27.70 (-0.49), SHPG: 178.46 (+7.97), SLXP: 137.38 (+4.96), MYL: 48.77 (+1.39), ABBV: 52.90 (-1.73)
Pfizer (PFE) Breaks Through Support at $28.31
Comtex SmarTrend(R) - Wed Oct 15, 10:40AM CDT
Shares of Pfizer (NYSE
PFE: 27.70 (-0.49)
AbbVie Backs Away From Shire Takeover After Tax Changes
at The Street - Wed Oct 15, 9:27AM CDT
The Dublin target insists the deal should go ahead and notes that it's in line for a $1.635 billion breakup fee if it collapses.
MDT: 61.81 (-0.44), SHPG: 178.46 (+7.97), PFE: 27.70 (-0.49), COV: 85.50 (-0.36), ABBV: 52.90 (-1.73)
Johnson & Johnson and Bristol-Myers Squibb’s New Collaboration Just the Tip of the Iceberg
Brian Orelli, The Motley Fool - Motley Fool - Wed Oct 15, 7:45AM CDT
If one drug is good, two drugs must be better. That seems to be what Johnson & Johnson and Bristol-Myers Squibb are thinking with the clinical trial collaboration agreement they entered to test Johnson & Johnson's Imbruvica with...
JNJ: 96.78 (-1.43), PCYC: 109.14 (+1.11), PFE: 27.70 (-0.49), MRK: 53.43 (-1.30), BMY: 49.22 (+0.26), NVS: 85.02 (-1.20)
FDA Sends Mixed Message On Safety of Pfizer inc.'s Chantix
Brian Orelli, The Motley Fool - Motley Fool - Wed Oct 15, 7:35AM CDT
Sales of Pfizer 's Chantix were knocked down a few years ago when the Food and Drug Administration slapped a black box warning on the smoking cessation drug after reports of patients experiencing neuropsychiatric events, including thoughts of...
PFE: 27.70 (-0.49), GSK: 42.88 (-0.25)
European Stocks Fall on Continued Worries Over Eurozone Economy
at The Street - Wed Oct 15, 4:58AM CDT
European stocks fall on Wednesday, failing to take their cue from a largely positive day in Asia as investors continue to worry about the outlook for the eurozone economy.
SHPG: 178.46 (+7.97), QCOM: 71.14 (-0.06), PFE: 27.70 (-0.49), MCHP: 39.19 (+1.46), AZN: 67.56 (-0.85), ABBV: 52.90 (-1.73)
Global Partial Seizure Clinical Trials Review, H2, 2014
M2 - Wed Oct 15, 3:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8gwn27/partial_seizure) has announced the addition of the "Partial Seizure Global Clinical Trials Review, H2, 2014" report to their offering. Partial Seizure Global Clinical Trials Review, H2, 2014 provides data on the Partial Seizure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Partial Seizure. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Partial Seizure. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Partial Seizure Therapeutics Clinical Trials - UCB S.A. - Pfizer Inc. - Eisai Co., Ltd. - Novartis AG - Johnson & Johnson - GlaxoSmithKline plc - Bial - Portela & Ca, S.A. - SK Holdings Co., Ltd. - Upsher-Smith Laboratories, Inc. - Abbott Laboratories - National Institute of Neurological Disorders and Stroke - Emory University - Oregon Health & Science University - Kyoto University - National Center for Complementary and Alternative Medicine - Hadassah Medical Organization - University of Pennsylvania - Lawson Health Research Institute - Massachusetts General Hospital - University of California, Davis For more information visit http://www.researchandmarkets.com/research/8g...al_seizure
JNJ: 96.78 (-1.43), ABT: 39.99 (-0.02), PFE: 27.70 (-0.49), GSK: 42.88 (-0.25), NVS: 85.02 (-1.20)